Residency · Residency · Nuclear Medicine
Radiopharmaceutical Regulations and USP 825
Regulatory Framework Overview
Federal Agencies
The regulation of radiopharmaceuticals in the United States involves multiple federal agencies with overlapping jurisdictions. The Nuclear Regulatory Commission (NRC) regulates reactor-produced radionuclides including Tc-99m, I-131, Mo-99, and Lu-177. Thirty-nine Agreement States have entered into agreements with the NRC to regulate radioactive materials within their borders independently. The FDA regulates radiopharmaceuticals as drugs, approving new agents through the NDA/ANDA pathway or under exploratory IND protocols. The Department of Transportation (DOT) governs the shipping of radioactive materials, the EPA oversees radioactive waste disposal, and state pharmacy boards regulate pharmacy practice including nuclear pharmacy operations.
NRC Licensing
NRC licensing provides the legal framework for the medical use of radioactive materials. A specific license authorizes the use of particular radionuclides for designated purposes, which is the arrangement at most community hospitals. A broad scope license provides greater flexibility in the types and quantities of materials that can be used and is typically held by academic medical centers and large institutions. Several categories of authorized personnel are defined within this framework. The Authorized User (AU) is the physician authorized to prescribe, prepare, and administer radiopharmaceuticals, with different regulatory sections governing different uses: 10 CFR 35.200 covers imaging and localization studies, 10 CFR 35.300 covers therapeutic uses requiring a written directive, 10 CFR 35.390 covers I-131 therapy above 33 mCi, 10 CFR 35.396 covers parenteral therapy such as Lu-177 and Ra-223, and 10 CFR 35.1000 covers emerging technologies. The Authorized Nuclear Pharmacist (ANP) is authorized to prepare radiopharmaceuticals, and the Radiation Safety Officer (RSO) oversees the institution's radiation safety program compliance.
USP Chapter 825
Purpose and Scope
USP General Chapter 825 (Radiopharmaceuticals -- Preparation, Compounding, Dispensing, and Repackaging) establishes minimum standards for handling radiopharmaceuticals across all practice settings, including nuclear pharmacies, hospital nuclear medicine departments, and PET centers. Its enforceability depends on adoption by individual state boards of pharmacy, which varies. A central organizing principle of USP 825 is the distinction between different categories of radiopharmaceutical preparation, each with its own level of regulatory stringency.
Categories of Preparation
Prepared radiopharmaceuticals are FDA-approved products handled according to the manufacturer's instructions, such as Tc-99m kit reconstitution and FDG dose drawing. These carry the least stringent requirements and represent standard nuclear pharmacy practice. Compounded radiopharmaceuticals are preparations not made according to FDA-approved instructions, including modified formulations such as autologous white blood cell labeling. These require more rigorous standards, including compounding-specific training for personnel. Nonsterile compounding is rarely applicable, limited mainly to research applications and oral preparations.
| Category | Definition | Examples | Facility Requirement | Personnel Requirement |
|---|---|---|---|---|
| Prepared | FDA-approved, per manufacturer instructions | Tc-99m kit prep, FDG dose drawing | ISO 5 PEC in ISO 7 or SCA | Standard training |
| Compounded (sterile) | Not per FDA-approved instructions | WBC labeling, research agents | ISO 5 PEC in ISO 7 cleanroom | Compounding-specific training |
| Nonsterile compounding | Oral/non-injectable | Research capsules | Less stringent | Compounding-specific training |
Key Requirements
Personnel Qualifications
All personnel involved in radiopharmaceutical preparation must be trained in aseptic technique and radiation safety, with competency assessments documented and continuing education requirements met. A designated supervising authorized individual oversees the operation.
Facilities and Engineering Controls
Sterile compounding requires classified environments: an ISO 5 (Class 100) primary engineering control -- either a laminar airflow workbench or a biosafety cabinet -- housed within an ISO 7 (Class 10,000) cleanroom or segregated compounding area. Shielded workstations with L-blocks, leaded glass, and syringe shields are needed for radiation protection. Proper ventilation with appropriate positive or negative pressure differentials must be maintained depending on the preparation type. A fundamental practical tension exists between radiation safety requirements, which favor containment (negative-pressure hoods), and pharmaceutical standards, which require clean environments with positive-pressure airflow.
Aseptic Technique
Garbing requirements include shoe covers, hair covers, face masks, sterile gloves, and gowns. Hand hygiene protocols must be followed rigorously. Personnel must undergo media fill testing to validate aseptic competency, and surface cleaning and disinfection protocols must be maintained.
Beyond Use Dating (BUD)
For prepared radiopharmaceuticals, the beyond use date follows the manufacturer's labeling, which is usually limited by radioactive decay to 6 to 12 hours. For compounded sterile preparations, shorter BUDs apply when products are prepared outside ideal conditions. Both radiochemical stability and sterility must be considered when establishing the BUD.
Quality Assurance
A comprehensive quality assurance program includes written standard operating procedures, environmental monitoring (surface and air sampling for cleanrooms), equipment calibration and maintenance (dose calibrators, survey meters), documentation of all preparations with QC results and adverse events, and root cause analysis for any errors.
Controversy and Implementation Challenges
USP 825 has generated considerable debate within the nuclear medicine community. The cost of upgrading facilities to meet cleanroom requirements is substantial, posing particular challenges for small departments. The inherent tension between radiation containment and clean environment standards means that hot cells and shielded fume hoods may not easily meet ISO cleanroom airflow requirements. Enforcement is inconsistent because not all states have adopted USP 825. Some practitioners argue that certain requirements, such as full gowning and environmental monitoring, are overly burdensome for radiopharmaceuticals with short physical half-lives, noting that Tc-99m decays so rapidly that the infection risk window is inherently brief. Others contend that radiation's self-sterilizing properties should warrant modified requirements. There is concern that strict compliance may reduce radiopharmaceutical availability in resource-limited settings.
Written Directives
Requirements (10 CFR 35.40)
A written directive is legally required before administration of I-131 sodium iodide above 30 microCi, any therapeutic radiopharmaceutical, and any treatment involving sealed sources. The directive must specify the patient's identity, the radiopharmaceutical, dosage, and route of administration, and must be signed and dated by the authorized user before administration. In emergencies, a verbal directive is permitted but must be documented in writing within 48 hours.
Medical Events
A medical event, as defined by 10 CFR 35.3045, occurs when an administration results in a dose to the wrong patient, the wrong radiopharmaceutical, the wrong route of administration, a dose differing from the written directive by more than 20% or delivered to the wrong treatment site by more than 20%, or a total dose exceeding 150% of the prescribed dose. Medical events must be reported to the NRC by telephone within 1 calendar day and in writing within 15 days. The patient must be notified unless the referring physician determines that notification would be harmful. A documented root cause analysis with corrective actions is required.
Radiation Safety in the Nuclear Pharmacy
Personnel Monitoring
Radiation workers wear dosimetry devices -- film badges, OSL dosimeters, or TLDs -- at collar level to measure deep dose equivalent. Ring dosimeters are worn for extremity monitoring during dose preparation. When a female worker formally declares pregnancy, a lower dose limit of 500 mrem for the entire gestation period applies. An ALARA program with investigation levels guides dose optimization.
Contamination Control
Removable contamination surveys (wipe tests) are performed regularly. Action levels require decontamination when contamination exceeds 200 dpm per 100 cm^2 in unrestricted areas. Spill procedures follow a contain-notify-decontaminate-survey sequence. Fume hoods are required when working with volatile radionuclides such as I-131 and Xe-133.
Waste Management
Decay-in-storage is the most common waste management strategy for short-lived radionuclides. Material is held for 10 half-lives, surveyed to confirm that activity has reached background levels, and then disposed of as regular waste after all radioactive labels have been removed. Long-lived radioactive waste is transferred to a licensed disposal facility. Sharps waste must be managed according to both biohazard and radiation safety protocols. Patient excreta from released patients is generally not regulated.
<image>A facility layout diagram of a compliant nuclear pharmacy showing the relationship between the cleanroom (ISO 7 buffer area), the primary engineering control (ISO 5 laminar airflow hood or hot cell), the anteroom for garbing, and the surrounding unclassified areas. Show the airflow direction (positive pressure from clean to less clean areas), shielded workstations with L-blocks, dose calibrator, QC testing area, generator storage, and radioactive waste decay-in-storage area. Label the personnel flow and material flow paths.</image>
<image>A decision flowchart for classifying radiopharmaceutical preparations under USP 825. Start with the question: Is this an FDA-approved product prepared per manufacturer instructions? If yes, classify as prepared radiopharmaceutical with standard requirements. If no, determine if it is a sterile or nonsterile compounded preparation and apply corresponding stricter requirements. Include examples at each branch (Tc-99m kit preparation, FDG dose drawing, WBC labeling, research compounds) and the associated facility, personnel, and BUD requirements for each category.</image>
Clinical Pearls
USP 825 establishes minimum standards for radiopharmaceutical preparation. Familiarity with its categories -- prepared versus compounded -- and their respective requirements is essential for any physician overseeing a nuclear medicine program.
The authorized user bears ultimate responsibility for the radiopharmaceutical administered to the patient, including verification of the correct patient, correct drug, correct dose, and correct route of administration.
Written directives are legally required for all therapeutic radiopharmaceutical administrations (I-131 above 30 microCi, Lu-177, Ra-223, and others). Failure to obtain a written directive before administration constitutes a medical event.
A medical event must be reported to the NRC within 1 calendar day by telephone. Knowing the precise definition and reporting timeline is essential for regulatory compliance.
The tension between radiation safety (containment with negative-pressure hoods) and USP sterility standards (positive-pressure clean environments) is a real practical challenge. Hot cells and shielded hoods must be validated to meet both sets of requirements simultaneously.
Mo-99 and aluminum breakthrough testing on Tc-99m generators is a regulatory requirement, not optional. Every result must be documented.
Decay-in-storage is the primary waste management strategy for Tc-99m and other short-lived radionuclides. Material is held for 10 half-lives, surveyed to confirm background activity levels, and then disposed of as regular waste.
References
- USP General Chapter <825>: Radiopharmaceuticals — Preparation, Compounding, Dispensing, and Repackaging. United States Pharmacopeia. 2020.
- NRC 10 CFR Part 35: Medical Use of Byproduct Material. Nuclear Regulatory Commission.
- Norenberg JP, et al. USP <825> and its impact on nuclear pharmacy practice. J Nucl Med Technol. 2021;49(3):195-201.
- Hung JC. USP General Chapter <825>: challenges and opportunities. J Nucl Med. 2020;61(6):781-783.
